Nuvation Bio
NUVB
121 hedge funds and large institutions have $317M invested in Nuvation Bio in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 29 reducing their positions, and 19 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 29
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
2% more funds holding
Funds holding: 119 → 121 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6.25% less ownership
Funds ownership: 71.5% → 65.24% (-6.3%)
37% less capital invested
Capital invested by funds: $503M → $317M (-$186M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.36M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.32M |
| 3 |
Goldman Sachs
New York
|
+$1.14M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$1.1M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$771K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$15.7M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$14.1M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.81M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.73M |
NUVB Hedge Fund Activity: Q3 2022 in Review
121 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q3 2022, worth a combined $317M — down 37% from $503M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NUVB positions and 19 closed out — a net gain of 3 holders — while 41 added to existing stakes and 29 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $2.36M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.7M sold.
- 121 institutional investors held Nuvation Bio (NUVB) as of Q3 2022, up from 119 in Q2 2022.
- Funds reported $317M of Nuvation Bio stock for Q3 2022, down 37% quarter-over-quarter.
- 22 funds opened new Nuvation Bio positions in Q3 2022 and 19 closed out, a net change of +3 holders.
- The largest Nuvation Bio buyer in Q3 2022 was T. Rowe Price Associates, an estimated $2.36M added.
- The largest Nuvation Bio seller in Q3 2022 was Avidity Partners Management, an estimated $15.7M sold.
Based on aggregated 13F filings for Q3 2022.